The impact of liver resection on the dihydrouracil: uracil plasma ratio in patients with colorectal liver metastases

Bart A W Jacobs, Nikol Snoeren, Morsal Samim, Hilde Rosing, Niels de Vries, Maarten J Deenen, Jos H Beijnen, Jan H M Schellens, Miriam Koopman, Richard van Hillegersberg

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PURPOSE: The dihydrouracil (DHU):uracil (U) plasma ratio is a promising marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient patients. The objective of this study was to determine the effect of liver resection on the DHU:U plasma ratio in patients with colorectal liver metastases (CRLM).

METHODS: An observational study was performed in which DHU:U plasma ratios in patients with CRLM were analyzed prior to and 1 day after liver resection. In addition, the DHU:U plasma ratio was quantified in six additional patients 4-8 weeks after liver resection to explore long-term effects on the DHU:U plasma ratio. Quantification of U and DHU plasma levels was performed using a validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay.

RESULTS: The median (range) DHU:U plasma ratio in 15 patients prior to liver resection was 10.7 (2.6-14.4) and was significantly reduced to 5.5 (< quantification limit (LLOQ-10.5) 1 day after resection (p = 0.0026). This reduction was caused by a decrease in DHU plasma levels from 112.0 (79.8-153) ng/mL to 41.2 (< LLOQ-160) ng/mL 1 day after resection (p = 0.0004). Recovery of the DHU:U plasma ratio occurred 4-8 weeks after liver resection, which was shown by a median (range) DHU:U plasma ratio in six patients of 9.1 (6.9-14.5).

CONCLUSION: Liver resection leads to very low DHU:U plasma ratios 1 day after liver resection, which is possibly caused by a reduction in DPD activity. Quantification of the DHU:U plasma ratios directly after liver resection could lead to false-positive identification of DPD deficiency and is therefore not advised.

Original languageEnglish
Pages (from-to)737-744
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number6
DOIs
Publication statusPublished - Jun 2018

Keywords

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic/adverse effects
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Bevacizumab/adverse effects
  • Capecitabine/adverse effects
  • Colorectal Neoplasms/blood
  • Female
  • Humans
  • Liver/surgery
  • Liver Neoplasms/blood
  • Male
  • Middle Aged
  • Organoplatinum Compounds/adverse effects
  • Oxaliplatin
  • Uracil/analogs & derivatives

Fingerprint

Dive into the research topics of 'The impact of liver resection on the dihydrouracil: uracil plasma ratio in patients with colorectal liver metastases'. Together they form a unique fingerprint.

Cite this